Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Amylyx Pharmaceuticals, Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, meaning each of the 3 pending matters is being reviewed by a different individual. This distribution shows no consolidation of cases under any single examiner. This decentralized approach means that the company's pharmaceutical innovations are subject to the individual interpretations of 3 different examiners, requiring a flexible prosecution strategy for each application.
The company's matters are spread across 2 distinct art units. With 3 pending office actions, the work is concentrated within 2 specialized divisions of the patent office. This presence in 2 art units indicates that the company's pharmaceutical innovations fall into a narrow range of technical classifications. The ratio of 3 actions to 2 art units shows that the company's filings are technically focused, allowing for a more specialized examination process within those specific groups of the patent office.
DAVID PAUL BOWLES is the busiest examiner for the portfolio, currently handling 1 pending office action. As all 3 distinct examiners are managing exactly 1 action each, the workload is uniform across the 3 pending matters. The management of 3 pending actions in 2 art units reflects the company's current patent activity. This balanced distribution across 3 examiners and 2 art units highlights the focused nature of the company's ongoing research and development efforts in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18372753 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | VALLE, ERNESTO | 34d |
| 19420848 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA | BOWLES, DAVID PAUL | — |
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19420848 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA | BOWLES, DAVID PAUL | 1654 | §103DP | Final Rejection | — | Pending | Dec 16, 2025 |
| 18372753 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | VALLE, ERNESTO | 1623 | §103Other | Non-Final OA | 34d | Pending | Sep 26, 2023 |
| 17285039 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | BEANE, RANDALL L | 1654 | §103§112Other | Non-Final OA | — | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial